Core Viewpoint - The stock of TEBIO experienced a decline of 2.00% on October 14, with a current price of 82.21 CNY per share and a market capitalization of 33.443 billion CNY. The company has seen a year-to-date stock price increase of 13.00% but has faced a slight decline in the recent trading periods [1]. Financial Performance - For the first half of 2025, TEBIO reported a revenue of 1.511 billion CNY, representing a year-on-year growth of 26.96%. The net profit attributable to shareholders was 428 million CNY, showing a year-on-year increase of 40.60% [2]. - Since its A-share listing, TEBIO has distributed a total of 577 million CNY in dividends, with 506 million CNY distributed over the past three years [3]. Shareholder and Market Activity - As of June 30, 2025, TEBIO had 8,439 shareholders, an increase of 13.00% from the previous period. The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2]. - The major shareholders include ETFs such as 华夏上证科创板50成份ETF and 易方达上证科创板50ETF, which have increased their holdings [3]. Company Overview - TEBIO, established on August 7, 1996, and listed on January 17, 2020, is based in Xiamen, Fujian Province. The company specializes in the research, production, and sales of recombinant proteins and long-acting modified drugs, with a revenue composition of 86.85% from antiviral drugs and 12.87% from blood/cancer drugs [1]. - The company operates within the pharmaceutical and biotechnology sector, specifically in the biopharmaceuticals category [1].

Summary of Conference Call Records Industry Overview - The A-share pharmaceutical sector underperformed the market in September 2025, declining by 1.7%, while the Hong Kong Hang Seng Healthcare Index rose by 5.2%, lagging behind the Hang Seng Index's 7.1% increase. The S&P 500 healthcare index increased by 1.6%, lower than the S&P 500's 3.5% rise [1][3][4]. Key Companies and Insights Changchun High-tech - Significant investment in R&D, focusing on pediatrics, oncology, and women's health. New products such as Meishiya and Jinbeixing are expected to ramp up quickly. Early-stage products like 047 and PD-1 agonist 120 have differentiated advantages, indicating substantial long-term growth potential [1][5]. Enhua Pharmaceutical - As a leader in the precision medicine sector, Enhua's main business is immune to centralized procurement risks. New product 60,001 is expected to mitigate risks associated with the procurement of etomidate. The company has a multi-pipeline layout in the CNS field, with a low current valuation [1][6]. Lepu Medical - Traditional business has stabilized, with strategic focus on innovative cardiovascular and metabolic drugs. Products like Mingweisheng's 109 injection and 105 injection are in clinical trials for obesity-related conditions. The company is also expanding into non-reimbursed areas [1][7]. Terbium Biologics - Recent approval for Pegbivac's use in chronic hepatitis B patients marks a significant clinical milestone. The growth hormone Tigebin is expected to drive performance in 2026 [1][8]. CRO Sector - Despite short-term impacts from safety legislation, the CRO industry is expected to recover. Companies like WuXi AppTec and Tigermed are recommended due to their strong market positions [2][9][22]. Market Trends and Predictions - The overall performance of the pharmaceutical sector in October 2025 is expected to be volatile, influenced by U.S.-China relations and tariff wars. However, the innovative drug supply chain remains promising. New recommendations include Changchun High-tech, Enhua Pharmaceutical, and Lepu Medical, while maintaining recommendations for Hengrui Medicine and Kelun Pharmaceutical [2][10]. Long-term Industry Outlook - The structural trends in the innovative drug industry and the advantages of China's engineering talent remain intact despite macro uncertainties. The external licensing model is considered safe under geopolitical conditions, with clear property rights [3][12]. Notable Companies to Watch - In October, companies such as Hengrui, Kangfang, and Rongchang Biologics are highlighted for their potential catalysts due to core asset data disclosures [2][13]. Additional Insights - The CRO sector is expected to see valuation recovery, with companies like WuXi AppTec projected to achieve double-digit revenue growth in Q3 2025 [22]. - JD Health is noted for its strong growth potential in the consumer healthcare sector, with revenue growth expected to exceed 20% in 2025 [23]. This summary encapsulates the key points from the conference call records, focusing on the pharmaceutical industry and specific companies within it.

Group 1 - Guangqi Technology's subsidiary signed mass production contracts for metamaterials totaling 516 million yuan, with products to be delivered by June 30, 2026 [1][2] - Mingyang Smart Energy plans to invest 1.5 billion pounds (approximately 14.21 billion yuan) to build a comprehensive wind power manufacturing base in Scotland, with the first phase expected to be operational by the end of 2028 [3][4] - Wentech Technology's control over Anshi Semiconductor is temporarily restricted due to a ministerial order from the Dutch government, affecting operational efficiency but not economic benefits [4][5] Group 2 - Baotailong's mine has officially resumed production with an annual design capacity of 900,000 tons [6] - New Lai Materials reported no significant changes in its operating environment, maintaining normal production and operations [7][8] - Tailing Micro plans to issue H-shares and list on the Hong Kong Stock Exchange [9] Group 3 - Times New Material announced a cash dividend of 0.07 yuan per share, totaling 65.18 million yuan, with the ex-dividend date set for October 17, 2025 [10] - Times New Material signed blade sales contracts totaling approximately 4.49 billion yuan, with 4.048 billion yuan from onshore wind projects and 442 million yuan from offshore projects [11][12] - Sunshine Nuohuo's new drug BTP4507 has received approval for clinical trials, targeting patients with poorly controlled primary hypertension [13] Group 4 - BGI Genomics expects to receive over 120 million USD in licensing fees for its CoolMPS sequencing technology [14] - Shandong Environmental Energy won a project for kitchen waste treatment in Xingtai, with an 8-year service period [15] - Kelun Pharmaceutical's product sac-TMT received approval for a third indication for treating advanced non-small cell lung cancer [16] Group 5 - Zhongzhi Holdings' major shareholder plans to publicly transfer 24.73% of the company's shares, which may lead to a change in control [17] - Yunnan Copper reported uncertainty regarding the future prices of cathode copper and gold, while maintaining normal operations [18] - Xiyang Co. announced that its tin smelting processing fees remain low despite rising tin prices [19] Group 6 - TEBIO's product Peginterferon has received approval for an additional indication for chronic hepatitis B treatment [20] - Yirui Biotech's major shareholder plans to reduce their stake by up to 3% due to personal funding needs [21] - China Nuclear Power reported a 14.95% year-on-year increase in power generation for the first three quarters, totaling 184.364 billion kWh [22] Group 7 - Shanghai Hejing's shareholder plans to reduce their stake by up to 1% due to personal funding needs [23] - Baili Tianheng's subsidiary triggered a milestone payment of 250 million USD from a collaboration with Bristol-Myers Squibb [24] - Hengdian East Magnetic expects a net profit increase of 50.1% to 65.2% year-on-year for the first three quarters [25]

Group 1 - The Shanghai Stock Exchange Sci-Tech Innovation Board 50 Index (000688) has shown a slight increase of 0.16% as of October 13, 2025, with notable gains from stocks such as Kingsoft Office (688111) up 10.92% and Teru Technology (688278) up 7.61% [1] - The Sci-Tech Innovation Board 50 ETF (588080) has experienced a decrease of 0.27%, with the latest price at 1.49 yuan, while it has accumulated a rise of 0.33% over the past two weeks [1] - The trading volume for the Sci-Tech Innovation Board 50 ETF reached 1.42% turnover with a total transaction value of 1.077 billion yuan, and the average daily transaction value over the past week was 2.362 billion yuan, ranking it among the top two comparable funds [1] Group 2 - As of September 30, 2025, the top ten weighted stocks in the Sci-Tech Innovation Board 50 Index accounted for 58.07% of the index, including companies like SMIC (688981) and Cambricon Technologies (688256) [2] - The recent Nobel Prize in Physics was awarded for the discovery of observable quantum effects at a macroscopic scale, which lays a theoretical foundation for the development of superconducting quantum computing [2][3] - The Transmon-type superconducting qubit, based on Josephson junctions, has become a mainstream technology, with institutions like Google and the University of Science and Technology of China launching high-performance superconducting quantum chips, indicating rapid industry development [3] Group 3 - The Sci-Tech Innovation Board 50 ETF (588080) tracks the performance of 50 large-cap, liquid stocks on the Sci-Tech Innovation Board, reflecting the overall performance of representative tech enterprises [4]

每经AI快讯，10月13日，特宝生物(688278.SZ)公告，公司产品派格宾联合核苷(酸)类似物用于成人慢性 乙型肝炎患者HBsAg持续清除的增加适应症已获国家药监局批准。此次获批基于临床试验结果，显示 31.4%患者在停药24周后实现HBsAg转阴且HBVDNA持续抑制。该适应症拓展显著提升派格宾市场潜 力，强化其在慢乙肝临床治愈领域的地位。 ...

Core Insights - Xiamen's capital market has significantly contributed to the growth of innovative enterprises, with a total of 68 domestic listed companies and a market capitalization of 797 billion yuan as of August 2025 [1][2] - The city has seen a 50% increase in A-share listed companies since the implementation of the registration system in 2019, with 23 new companies added [1][2] - Xiamen's listed companies are primarily engaged in sectors such as electronic information, biomedicine, and new materials, with over one-third classified as specialized and innovative enterprises [2][3] Market Development - The capital market in Xiamen is in an accelerated development phase, with 16 new overseas listed companies and 565 companies in the pipeline for listing [1][2] - The total R&D expenditure of listed companies reached 11.25 billion yuan in 2024, marking a 2.2% year-on-year increase, with an average R&D intensity of 6.23% in the manufacturing sector [3][4] Financial Ecosystem - Xiamen has established a multi-tiered capital market system, including the main board, ChiNext, and regional equity markets, providing comprehensive financing services for enterprises at different stages [1][6] - The private equity market has also expanded, with 321 private fund managers managing 203.4 billion yuan, reflecting a 6.23% increase [6][7] Policy Support - The Xiamen Securities Regulatory Bureau has implemented various policies to support the high-quality development of the capital market, including measures for technology innovation and mergers and acquisitions [4][5] - The bureau has facilitated the listing of 102 specialized and innovative enterprises on the newly established board, enhancing the service and cultivation functions of the regional equity market [7][8] Future Outlook - The Xiamen Securities Regulatory Bureau aims to leverage the reform of the Sci-Tech Innovation Board to identify high-quality technology enterprises with significant breakthroughs and strong commercial prospects [5][8] - The city plans to continue enhancing its financial ecosystem to support the growth of innovative enterprises and improve the quality and quantity of listed companies [8]

Market Overview - The A-share market showed a decline with the Shanghai Composite Index down by 0.94% closing at 3897.03 points, while the ChiNext Index fell by 4.55% to 3113.26 points, indicating a bearish trend across various indices [1][7] - The total market turnover was 25,341.46 billion, a decrease of 1,376.72 billion from the previous trading day, with 2,772 companies rising and 2,529 companies falling [8] Economic Insights - The People's Bank of China achieved a net withdrawal of 426.3 billion in the open market last week, indicating a tightening of liquidity [16][17] - In September, the number of new A-share accounts reached 2.94 million, a significant year-on-year increase of 61%, reflecting growing investor interest [22][23] Industry Dynamics - Qualcomm is under investigation by the State Administration for Market Regulation for failing to report its acquisition of Autotalks, which may accelerate the trend of domestic technology independence [26] - A strategic partnership was formed between Zhiyuan Robotics and Longqi Technology to deploy nearly 1,000 robots, marking a significant order in the domestic industrial robotics sector [28] - The Ministry of Commerce and the General Administration of Customs announced export controls on lithium batteries and artificial graphite anode materials, which could impact the supply chain [34] Company Updates - Taotao Automotive (301345.SZ) projected a net profit of 580 million to 620 million for Q3 2025, representing a year-on-year growth of 92.46% to 105.73% [41] - Special approval was granted to TeBao Bio (688278.SH) for an additional indication for its drug, enhancing its market competitiveness [43] - Wens Foodstuff Group (300498.SZ) reported a 15.16% decline in September pig sales revenue, while chicken sales revenue increased by 8.69% [45] - Muyuan Foods (002714.SZ) sold 5.573 million pigs in September, marking an 11% year-on-year increase [47] - Rongsheng Petrochemical (002493.SZ) completed its share buyback plan, acquiring 116.64 million shares, which is 1.17% of its total share capital [49]

Group 1 - The Ministry of Commerce criticized the U.S. for threatening high tariffs, stating that this approach is not the correct way to engage with China [1] - The State Administration for Market Regulation has initiated an investigation into Qualcomm for allegedly completing the acquisition of Autotalks without proper communication or notification [1] - The Ministry of Water Resources has activated a Level IV flood defense emergency response for Shanxi, Henan, and Shaanxi provinces due to significant rainfall and flooding [1] Group 2 - The National Postal Service reported that China's express delivery volume has surpassed 1.5 billion packages as of October 11, indicating stable growth in the consumer market [1] - The latest data from the National Astronomical Observatory revealed that the FAST telescope has discovered 1,152 pulsars, significantly exceeding the total number found by other international telescopes during the same period [1] - The Beijing Municipal Bureau of Economy and Information Technology announced plans to develop industrial tourism, aiming for 20 million visitors and 3 billion yuan in revenue by 2027 [1] Group 3 - Sany Heavy Industry has updated its listing materials on the Hong Kong Stock Exchange, indicating progress in its overseas listing process [1] - China Nuclear Power reported a 14.95% year-on-year increase in cumulative operational power generation for the first three quarters [4] - Tianshan Microelectronics is planning to list on the Hong Kong Stock Exchange [4]

受理号：CXSS2400023、CXSS2400024、CXSS2400025、CXSS2400026 证书编号：2025S03097、2025S03098、2025S03099、2025S03100 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 近日，厦门特宝生物工程股份有限公司（以下简称"公司"）收到国家药品监督管理局核准签发的《药品 注册证书》，公司产品派格宾联合核苷（酸）类似物用于成人慢性乙型肝炎患者的HBsAg持续清除的增 加适应症（以下简称"增加适应症"）上市许可申请获得批准。现将有关情况公告如下： 一、药品基本情况 药品名称：派格宾? 通用名称：聚乙二醇干扰素α-2b注射液 申请事项：药品注册（境内生产） 我国2022版《慢性乙型肝炎防治指南》中指出："对于部分适合条件的患者，应追求临床治愈（又称功 能性治愈）"，即停止所有治疗药物6个月或更长时间HBsAg持续清除伴HBV DNA持续抑制。HBsAg持 续清除是一个重要的临床治疗目标，目前被认为是获得HBV功能性治愈的标志。本次派格宾获批增加 适应症是基于一 ...

Group 1 - The Ministry of Commerce of China clarified that the recent export controls on rare earths are not a ban, and applications that meet regulations will be approved [2] - The U.S. Vice President indicated a willingness for rational negotiations with China regarding tariff threats, suggesting potential easing of tensions [2] - Wentech Technology criticized the Dutch government's actions against its subsidiary, stating it is based on geopolitical bias rather than factual risk assessment [2] Group 2 - The State Administration for Market Regulation in China has taken action against Qualcomm for failing to report a merger that may restrict competition, leading to an investigation [3] - A national conference emphasized the need for a modernized industrial technology innovation system to enhance high-quality technological supply [3] Group 3 - The Hainan provincial government is accelerating the construction of a free trade port, aiming for high-quality development and cooperation with global free zones [4] - Zhejiang province plans to build a modernized urban system by 2030, with a focus on enhancing GDP rankings and digital economy contributions [4] Group 4 - The Hong Kong government is participating in the IMF and World Bank annual meetings to discuss international financial trends and promote the potential of the Northern Metropolis and the Greater Bay Area [5] - Nearly 100,000 elderly residents from Hong Kong have chosen to settle in Guangdong province, indicating a trend in retirement preferences [6] Group 5 - A-shares have seen a recent adjustment after reaching new highs, with analysts suggesting a focus on policy-driven sectors and strong earnings reports for future investments [7] - The third-quarter earnings forecasts show a high percentage of companies expecting positive results, indicating market optimism [7] Group 6 - Fund companies are increasingly launching new products, with a significant portion being equity funds, reflecting renewed interest in equity assets [8] - Companies like Sany Heavy Industry and Baoma Tea have passed listing hearings in Hong Kong, indicating ongoing market activity [8] Group 7 - Recent export controls and licensing systems are seen as measures to protect national interests while potentially benefiting compliant enterprises in the global market [9] - The 138th Canton Fair is set to open with record participation, signaling resilience in China's foreign trade [11] Group 8 - Regulatory measures are being strengthened against the misuse of personal business loans in the real estate market, highlighting emerging risks [12] - The insurance sector is adapting to new regulations aimed at promoting high-quality development in non-auto insurance [12] Group 9 - Australia is considering a mineral resources agreement with the U.S. to support critical mineral projects, reflecting strategic resource management [13] - The global semiconductor industry anticipates significant investment in 300mm wafer fabs, indicating growth in technology manufacturing [14] Group 10 - Binance experienced technical issues during a market crash but maintained that core operations remained stable, emphasizing the need for responsible management [15] - The impact of recent market volatility on hedge funds and trading firms is being closely monitored, with potential risks of broader contagion [15] Group 11 - Global central bank leaders are set to discuss stock market bubbles and potential risks at the upcoming IMF and World Bank meetings, reflecting concerns over asset valuations [19] - Nvidia's CEO has sold a significant amount of stock, raising questions about insider trading and market confidence [20] Group 12 - Gold prices have reached historic highs, prompting banks to issue risk warnings regarding precious metal investments [21] - Silver prices have surged, causing liquidity issues in the market, highlighting the volatility in precious metals trading [21]